Market revenue in 2020 | USD 922.7 million |
Market revenue in 2028 | USD 1,266.1 million |
Growth rate | 4% (CAGR from 2020 to 2028) |
Largest segment | Reagents |
Fastest growing segment | Reagents |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Instruments, Reagents |
Key market players worldwide | Abbott Laboratories, Danaher Corp, BioMerieux SA, Roche Holding AG ADR, Bio-Rad Laboratories Inc, Agilent Technologies Inc, Becton Dickinson & Co, Hologic Inc, Illumina Inc, Grifols SA Ordinary Shares - Class A, Qiagen NV, Siemens Healthineers AG ADR, Sysmex Corp |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to infectious disease molecular diagnostics market will help companies and investors design strategic landscapes.
Reagents was the largest segment with a revenue share of 65% in 2020. Horizon Databook has segmented the Germany infectious disease molecular diagnostics market based on instruments, reagents covering the revenue growth of each sub-segment from 2018 to 2028.
In Germany, the incidence rate for hospital-acquired infections is 3.79 per 1,000 patient days in the public hospitals. This included infections such catheter-associated urinary tract infections, catheter-associated infections, and Ventilatoracquired Pneumonia (VAP).
These healthcare-associated infections are drug resistant, hence, use of molecular diagnostics facilitates selection of treatment. Furthermore, Germany has a strong healthcare system, which covers 90% of the population under the mandatory health insurance cover, enabling easy access to molecular diagnostics.
The most commonly diagnosed infections in the country are UTIs and acute upper respiratory tract infections. The country records over 75,000 cases of sepsis each year in the ICUs. Furthermore, STI prevalence is growing in the country, with Mycoplasma genitalium having a prevalence rate of 18.8%, followed by chlamydia at 12.7%.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany infectious disease molecular diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into Germany infectious disease molecular diagnostics market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account